1[1]Costell M, Gustafsson E, Aszodi A, et al. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol,1999,147:1109～1122.
2[2]Costell M,Carmona R,Gustafsson E,et al.Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice.Circ Res,2002,91:158～164.
3[3]Arikawa-Hirasawa E, Le AH, Nishino I, et al. Structural and functional mutations of the perlecan gene cause Schwartz-Jampelsyndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet,2002,70:1368～1375.
4[4]Belknap JK, Weiser-Evans MC, Grieshaber SS, et al. Relationship between perlecan and tropoelastin gene expression and cell replication in the developing rat pulmonary vasculature.Am J Respir Cell Mol Biol,1999,20:24～34.
5[5]Whitelock JM, Graham LD, Melrose J, et al. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol, 1999, 18:163～178.
6[6]Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med, 2000, 10:60～65.
7[7]Evanko SP, Raines EW, Ross R, et al. Proteoglycan distribution in lesions of atherosclerosis depends on lesionseverity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol, 1998, 152:533～546.
8[8]Nugent MA,Nugent HM,Iozzo RV,et al.Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia.Proc Natl Acad Sci USA,2000, 97:6722～6727 .
9[9]Chung IM,Gold HK,Schwartz SM,et al.Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment.J Am Coll Cardiol,2002, 40:2072～2081.
10[10]Nakahama M,Murakami T,Kusachi S,et al.Expression of perlecan proteoglycan in the infarct zone of mouse myocardial infarction.J Mol Cell Cardiol,2000,32:1087～1100.
2Fritsch EW,Heisel J,Rupp S.The failed back surgery syndrome:reasons,intraoperative findings,and long-term results:a report of 182 operative treatments.Spine(Phila Pa 1976),1996,21(5):626-633.
3Hu RW,Jaglal S,Axcell T,et al.A population-based study of reoperations after back surgery.Spine(Phila Pa 1976),1997,22(19):2265-2270.
4Robertson JT.Role of peridural fibrosis in the failed back:a review.Eur Spine J,1996,5 Suppl 1:S2-6.
5Ross JS,Obuchowski N,Zepp R.The postoperative lumbar spine:evaluation of epidural scar over a 1-year period.AJNR Am J Neuroradiol,1998,19(1):183-186.
6Laroccad H,Macnab I.The laminectomy membrane.Studies in its evolution,characteristics,effects and prophylaxis in dogs.J Bone Joint Surg Br,1974,56(3):545-550.
7Jiang X,Couchman JR.Perlecan and tumor angiogenesis.J Histochem Cytochem,2003,51(11):1393-1410.
8Knox S,Merry C,Stringer S,et al.Not all perlecans are created equal:interactions with fibroblast growth factor(FGF)2 and FGF receptors.J Biol Chem,2002,277(17):14657-14665.
9Cross MJ,Claesson-Welsh L.FGF and VEGF function in angiogenesis:signaling pathways,biological responses and therapeutic inhibition.Trends Pharmacol Sci,2001,22(4):201-207.
10da Costa RC,Pippi NL,Graca DL,et al.The effects of free fat graft or cellulose membrane implants on laminectomy membrane formation in dogs.Vet J,2006,171(3):491-499.
